MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Study Summary

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.

Conditions

Unresectable Pleural Mesothelioma

Interventions / Drugs

Volrustomig Pemetrexed Carboplatin Cisplatin Nivolumab Ipilimumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment825 participants

Primary Completion—

Lead SponsorAstraZeneca

Data Retrieved2026-04-11 02:55:19.910525+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.